PBH

AI Memo

Prestige Consumer Healthcare

As of 2026-10-22/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-10-22 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

—

Key catalyst

Fiscal 2027 second-quarter results • 2026-11-05

Base target: $50 / p=50% prob

Biggest risk

The outlook increase reflected acquisitions rather than a higher underlying-business forecast. Clear Eyes supply volatility, integration spending and roughly $2 billion of net debt constrain the case; reported EPS of $0.61 was well below adjusted EPS of $0.98. [#SEC-8K-2026-08-06]

Invalidation

Break below $39 or thesis failure.

What would change my mind?

Fiscal first-quarter revenue rose 6.5% to $265.7 million, with 3.2% organic growth and adjusted EPS of $0.98 versus $0.95 a year earlier. Continued organic growth, successful acquisitions and debt reduction could support a rerating. [#SEC-8K-2026-08-06]

Research note

Recommendation

—

Confidence

medium

As of

2026-10-22

Base target

$50

p=50%

Bull target

$60

p=25%

Bear target

$39

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Breathe Right and LaCorium integration
Cash conversion and deleveraging
Fiscal first-quarter revenue rose 6.5% to $265.7 million, with 3.2% organic growth and adjusted EPS of $0.98 versus $0.95 a year earlier.

BearKey bullets

Acquisition integration and Pillar5 capacity costs create a material gap between reported and adjusted earnings.
[#SEC-8K-2026-08-06]
Clear Eyes supply volatility and a challenging consumer backdrop may offset growth in other categories.

WatchKey bullets

Fiscal 2027 second-quarter results

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $50 (p=50%)

Target spread vs base: +20% / -22%

Scenario probabilities

Bull Target: $60 (p=25%)Base Target: $50 (p=50%)Bear Target: $39 (p=25%)

Commentary

The supplied recent-news item is unrelated to PBH, and no verified post-result price-reaction attribution, analyst revisions, options, short-interest, employee or social measures are available. The deterministic return prior has turned modestly positive since the prior baseline, but the November 5 release remains the principal test. Sentiment fields set to zero denote unavailable data, not measured neutrality.

As of 2026-10-22 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

Breathe Right and LaCorium integration
Cash conversion and deleveraging

Scenarios

Bull Target (Scenario probability)

$60 / p=25% prob

Base Target (Scenario probability)

$50 / p=50% prob

Bear Target (Scenario probability)

$39 / p=25% prob

Analysis 2026-10-22 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.00

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-11-05
Fiscal 2027 second-quarter results
PBH scheduled its second-quarter release for November 5. The key test is whether organic sales and adjusted earnings support the FY2027 outlook of $1.290–$1.315 billion in revenue and $4.55–$4.65 in adjusted diluted EPS. The August outlook increase was entirely attributable to acquisitions, not an increase in the underlying-business forecast. [#PR-EARNINGS-2026-10-14] [#SEC-8K-2026-08-06]
Prob 60.00% • Move 7.00% • Priced-in 50.00%

Short-term Catalysts

Next few weeks

No short-term catalysts

Long-term Catalysts

Months to a year

Breathe Right and LaCorium integration
2027-03-31
Breathe Right contributed about $5.9 million in the fiscal first quarter after closing in June; LaCorium closed in July. Sustained brand growth and successful integration could improve returns, but the contribution beyond the reported quarter remains unproven. [#SEC-8K-2026-08-06]
Prob 60% • Move 10% • Priced-in 45%
Cash conversion and deleveraging
2027-03-31
Management reported approximately $2 billion of net debt at June 30 and expects to deleverage. The next several quarters should show whether cash generation persists after the first quarter's working-capital timing benefit and acquisition costs. [#SEC-8K-2026-08-06]
Prob 55% • Move 6% • Priced-in 40%

Risks

Acquisition integration and Pillar5 capacity costs create a material gap between reported and adjusted earnings. [#SEC-8K-2026-08-06]
Clear Eyes supply volatility and a challenging consumer backdrop may offset growth in other categories. [#SEC-8K-2026-08-06]
First-quarter adjusted free cash flow benefited from working-capital timing; its run rate may not persist. [#SEC-8K-2026-08-06]
The Senior Vice President of Operations retired effective August 14, adding a transition to monitor during integration; the filing does not establish an operating disruption. [#8-K-2026-08-14]

Peers

Symbol	Summary
PRGO	Perrigo's OTC and consumer self-care products make it an operating comparator, although its portfolio and financial profile differ from PBH's. Perrigo investor relations
HLN	Haleon overlaps in consumer-health categories, but its much larger global scale limits direct valuation comparison. Haleon investor relations

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-10-22

Loading AI feed…

Symbol

Summary

PRGO

Perrigo's OTC and consumer self-care products make it an operating comparator, although its portfolio and financial profile differ from PBH's. Perrigo investor relations

HLN

Haleon overlaps in consumer-health categories, but its much larger global scale limits direct valuation comparison. Haleon investor relations